Dr. Song’s research is focused on the study of G-protein coupled receptor (GPCR) signaling. G protein coupled receptors, a family of membrane signaling proteins, are the targets of half of the drugs on the market today. Her past research shows that some GPCRs function as dimer or oligomers, and that specific binding molecules regulate receptor signaling and trafficking. Dr. Song is currently focusing primarily on two projects: the study of parathyroid hormone (PTH) receptor signaling in vascular cells and the study of the glucagon-like peptide 1 receptor signaling in the pancreatic islets.
During the past few years, Dr. Song has concentrated on determining the molecular mechanism underlying vascular disease, with particular emphasis on the role of PTHrP and the PTH receptor signaling in the development of arterial restenosis. Her research has revealed some of the mechanisms regulating expression and signal transduction of the PTH1R in vascular smooth muscle cells. Indeed, these molecules are endogenously expressed in vascular smooth muscle cells and play a key role in mediating proliferation and migration of vascular smooth muscle cells, events that are critical for the development of restenosis (the process of occlusion of an artery) following angioplasty. Dr. Song is also interested in the function of EBP50 (Ezin binding protein, NHERF1) a scaffolding protein in the vasculature. She showed that EBP50 contributes to cell-specific signaling by the PTH receptor and contributes to vascular smooth muscle cell proliferation and migration. These observations suggest that targeting EBP50 represents a completely novel potential approach for treating this important complication of a commonly used surgical procedure.
Dr. Song is also involved in the study on glucagon-like peptide 1 receptor (one of the GPCRs) function in pancreatic islets. In particular, the role of the adaptor protein Caveolin-1 in the regulation of receptor expression and function is under investigation. Furthermore, her research aims to determine the role of Caveolin-1 in determining the efficacy of GLP-1R agonists in stimulating insulin secretion and ß cell proliferation in vivo.
Back to Top